1 - Million STRONG, we got plenty of Targets, Killing Cancers and all that. Getting our Assets back, the list goes on. Just so we can Keep on...1 - Million STRONG, we got plenty of Targets, Killing Cancers and all that. Getting our Assets back, the list goes on. Just so we can Keep on KILLING CANCER and educate the World with all our Advanced Tech and Critical Drug Development Targets...

And we wonder why all this takes so long!
We are FIGHTERS, for the People, by the People.

So here we go!
Lets see who can guess who is next on the "new Album" 1 - Million Strong, Greatest Hits List ??

tmsearch.uspto.gov/bin/gate.exe

We've sent plenty of letters and they choose to ignore us, "HINT", I think Montel Williams told them to IGNORE us, I "could" be wrong.

WE SHALL SEE SHORTLY. (active 2018 - 2020) we shall see as their USAGE caused irreparable damage as they GREW using our Name right while we were KILLING CANCER at Harvard.

HOW GOOD WAS THAT FOR THEM during those years ???
They used our GOOD NAME, while we were the Ones Killing Cancer at Harvard.

Hmmmmm, we are almost there Folks.
*** Plenty of "Come to Jesus" moments on their way.
Just remember 1 - million Strong, WE are the ones Killing Cancer.

While others use our name and try to steal our assets.

tmsearch.uspto.gov/bin/gate.exe

skip navigationU S P T O Seal [home] United States Patent and Trademark Office
Home|Site Index|Search|FAQ|Glossary|Contacts|eBusiness|eBiz alerts|News
Trademarks > Trademark Electronic Search System (TESS)

TESS was last updated on Wed Apr 27 03:32:24 EDT 2022

TESS Homepage New User Form Structured Form Search Free Form Search Browse Dictionary Index Search OG Bottom On-line Help
Please logout when you are done to release system resources allocated for you.
Record 1 out of 1
LINK TO TSDR LINK TO TRADEMARK ASSIGNMENTS LINK TO TTAB VUE ( Use the "Back" button of the Internet Browser to return to TESS)
Mark Image
Word Mark CANNABISSCIENCE
Goods and Services (ABANDONED) IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Drug delivery agents that provide controlled release of the active ingredients for a wide variety of cannabinoid pharmaceuticals; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Therapeutic pharmaceutical for the treatment and prevention of inflammatory bowel disease; Pharmaceutical preparations for use in gastroenterology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Therapeutic pharmaceutical for the treatment and prevention of neurodegenerative disease; Therapeutic pharmaceutical for the treatment and prevention of neurological disorders; Pharmaceutical preparations for use in neurology; Pharmaceutical preparations and substances for the treatment and prevention of psychiatric diseases and disorders; Therapeutic pharmaceutical for the treatment and prevention of autoimmune conditions; Therapeutic pharmaceutical for the treatment and prevention of inflammation; Pharmaceutical preparations for the treatment and prevention of immune system related diseases and disorders; Therapeutic pharmaceutical for the treatment and prevention of pain; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Therapeutic pharmaceutical for the treatment of infections; Therapeutic pharmaceutical for the treatment of drug-resistant infections; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical agents affecting sensory organs; Analgesic and muscle relaxant pharmaceutical preparations; Pharmaceutical preparations for use in urology; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in opthalmology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations for skin care; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Ocular pharmaceuticals; Antibacterial pharmaceuticals; Pharmaceuticals, namely, anti-infectives. FIRST USE: 20090507. FIRST USE IN COMMERCE: 20090507
Mark Drawing Code (3) DESIGN PLUS WORDS, LETTERS, AND/OR NUMBERS
Design Search Code 01.09.25 - Asteroids ; Atoms ; Meteors
Serial Number 88044465
Filing Date July 19, 2018
Current Basis 1A
Original Filing Basis 1A
Owner (APPLICANT) Cannabis Science, Inc. CORPORATION NEVADA 19800 MacArthur Blvd., Suite #300 Irvine CALIFORNIA 92612
Attorney of Record Faiyaz Dean
Disclaimer NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "CANNABIS SCIENCE" APART FROM THE MARK AS SHOWN
Description of Mark The color(s) green and teal is/are claimed as a feature of the mark. The mark consists of a stylized molecule, which consists of 4 separate atoms, three of which are light green with a white border, these three atoms are attached to a central dark green atom, which also has a white border. The word "CANNABIS" is written in bright green to the right of the molecule and the word "SCIENCE" is written in dark green to the right of the word "CANNABIS", in dark green. The word "OTC: CBIS" is written in black below the word "SCIENCE".
Type of Mark TRADEMARK
Register PRINCIPAL
Live/Dead Indicator DEAD
Abandonment Date August 13, 2020 Show more